Drug induced phospholipidosis: an acquired lysosomal storage disorder
about
LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectivesLipoprotein X Causes Renal Disease in LCAT DeficiencyA Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant TuberculosisHost-directed antimicrobial drugs with broad-spectrum efficacy against intracellular bacterial pathogens.Structure and function of lysosomal phospholipase A2 and lecithin:cholesterol acyltransferase.Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis of Fabry diseaseStrategies, models and biomarkers in experimental non-alcoholic fatty liver disease researchThe Application of Paraphenylenediamine Staining for Assessment of Phospholipidosis.Comparative analysis of lipotoxicity induced by endocrine, pharmacological, and innate immune stimuli in rat basophilic leukemia cells.Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).Functional inhibition of acid sphingomyelinase by Fluphenazine triggers hypoxia-specific tumor cell death.Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.Molecular biomarkers of phospholipidosis in rat blood and heart after amiodarone treatment.An Immunohistochemical Investigation of Renal Phospholipidosis and Toxicity in Rats.B-13 progenitor-derived hepatocytes (B-13/H cells) model lipid dysregulation in response to drugs and chemicals.Autophagy function and its relationship to pathology, clinical applications, drug metabolism and toxicity.Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening.One man's poison is another man's meat: using azithromycin-induced phospholipidosis to promote ocular surface health.A fluorogenic phospholipid for the detection of lysosomal phospholipase A2 activity.The 3D OrbiSIMS-label-free metabolic imaging with subcellular lateral resolution and high mass-resolving power.Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.A Carbon Nanotube Optical Reporter Maps Endolysosomal Lipid Flux.The physiological determinants of drug-induced lysosomal stress resistance.Alterations in endo-lysosomal function induce similar hepatic lipid profiles in rodent models of drug-induced phospholipidosis and Sandhoff disease.The Effect of Solithromycin, a Cationic Amphiphilic Drug, on the Proliferation and Differentiation of Human Meibomian Gland Epithelial Cells.Harmful at non-cytotoxic concentrations: SiO2-SPIONs affect surfactant metabolism and lamellar body biogenesis in A549 human alveolar epithelial cells.From the Cover: Potentiation of Drug-Induced Phospholipidosis In Vitro through PEGlyated Graphene Oxide as the Nanocarrier.Drug-induced steatohepatitis
P2860
Q28078899-984030D7-EE36-41DA-ACF4-58591D4DB352Q28550403-BECD7E8F-6003-4DF3-B93E-CE13442310A0Q33939074-1AB6DBC5-E491-4E03-AF96-41E64912839DQ34026297-A48C2CA3-EB11-46E3-ACE2-77B16366A49BQ35428677-0BD5FE66-9A3D-4651-882E-EE5F4541D6AAQ35981136-D552FB39-A3E8-4126-BC16-6B3D8BA62168Q36129673-9DEDB06C-0052-42E6-AF3E-4BBE2B32343EQ36171786-E7032FE6-D80C-4F09-90D9-E0DA16FE8132Q36585999-F4806366-B55F-4901-B3AF-4A068DE151B2Q36717186-83117B47-5D7C-4DE5-A1CB-BD27D3E81442Q37745415-8A239124-D191-413B-B97B-FD0CD8FBF7C0Q38247442-4EFC8FC6-25E0-478C-A1E7-69DDA058F6AAQ38468007-967AA261-09BE-4FB1-A1AD-78949B9CDE8EQ38618764-82896081-6564-4F90-9936-95DBE5AFE8F9Q38702009-79160775-7A03-4D7A-B37B-F3D00E915037Q38967211-37B5EA89-D76C-4223-8D16-BE4E4EAD2DD0Q39346006-5C324316-C8FC-4918-8B0F-D159374D3D30Q39738019-6F27C320-8EA2-4034-81B6-EEF746B49529Q42009431-68A33AC0-9DE7-4CA7-B86A-BB6FB6532CBCQ46262837-299BCA03-364D-42E0-A606-B1AFDE18B3F4Q46777308-965243CA-03E4-43F6-A00C-492B5C2A63E3Q47130016-5930F040-1E1D-4793-9B7F-FFC63ADFDACDQ47167970-B313B518-0203-4A7E-A39D-465060F3AE38Q48320658-FAF98F50-56AC-4605-8367-D428B0348D2FQ50128650-759FF1A2-CE12-4EBE-8C69-D600CDF2D1B7Q50730700-AA7A50EB-6C61-4EB6-9FF8-661964DC6CB1Q51237623-FAD5648A-54E6-4643-A0F3-D8A215556A5BQ56541717-0E135DC8-6FBC-44FA-96F4-339128A6C8F8
P2860
Drug induced phospholipidosis: an acquired lysosomal storage disorder
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Drug induced phospholipidosis: an acquired lysosomal storage disorder
@ast
Drug induced phospholipidosis: an acquired lysosomal storage disorder
@en
Drug induced phospholipidosis: an acquired lysosomal storage disorder
@nl
type
label
Drug induced phospholipidosis: an acquired lysosomal storage disorder
@ast
Drug induced phospholipidosis: an acquired lysosomal storage disorder
@en
Drug induced phospholipidosis: an acquired lysosomal storage disorder
@nl
prefLabel
Drug induced phospholipidosis: an acquired lysosomal storage disorder
@ast
Drug induced phospholipidosis: an acquired lysosomal storage disorder
@en
Drug induced phospholipidosis: an acquired lysosomal storage disorder
@nl
P2860
P3181
P1476
Drug induced phospholipidosis: an acquired lysosomal storage disorder
@en
P2093
James A. Shayman
P2860
P304
P3181
P356
10.1016/J.BBALIP.2012.08.013
P407
P577
2013-03-01T00:00:00Z